About CVRx
CVRx is a company based in Minneapolis (United States) founded in 2001. CVRx has raised $368.5 million across 9 funding rounds from investors including SVB, DaVita and Oxford Finance. The company has 206 employees as of December 31, 2024. CVRx offers products and services including Barostim. CVRx operates in a competitive market with competitors including Sequana Medical, Adona Medical, Element Science, V-Wave and Ancora Heart, among others.
- Headquarter Minneapolis, United States
- Employees 206 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cvrx, Inc.
-
Annual Revenue
$51.29 M (USD)30.53as on Dec 31, 2024
-
Net Profit
-$59.97 M (USD)-45.55as on Dec 31, 2024
-
EBITDA
-$58.87 M (USD)-38.26as on Dec 31, 2024
-
Total Equity Funding
$368.5 M (USD)
in 9 rounds
-
Latest Funding Round
$50 M (USD), Series F
Jul 07, 2020
-
Investors
SVB
& 20 more
-
Employee Count
206
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CVRx
CVRx is a publicly listed company on the NASDAQ with ticker symbol CVRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CVRx
CVRx offers a comprehensive portfolio of products and services, including Barostim.
Delivers electrical pulses to improve heart failure symptoms and quality of life.
People of CVRx
Unlock access to complete
Unlock access to complete
Funding Insights of CVRx
CVRx has successfully raised a total of $368.5M across 9 strategic funding rounds. The most recent funding activity was a Series F round of $50 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CVRx
CVRx has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, DaVita and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked |
Investor details for CVRx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CVRx
Investment portfolio details for CVRx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CVRx
Detailed financials for CVRx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cvrx Comparisons
Peer comparison for CVRx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CVRx
CVRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sequana Medical, Adona Medical, Element Science, V-Wave and Ancora Heart, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Implantable battery-powered pumps for ascites removal are developed.
|
|
| Locked | Locked | Locked |
Medical devices for heart failure management are developed.
|
|
| Locked | Locked | Locked |
Wearable patch defibrillators are developed for sudden cardiac arrest treatment.
|
|
| Locked | Locked | Locked |
Implantable inter-atrial shunts are developed to treat chronic heart failure.
|
|
| Locked | Locked | Locked |
Minimally invasive ventriculoplasty system for heart failure and FMR
|
Detailed competitors of CVRx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cvrx
Complete news archive for CVRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CVRx
CVRx was founded in 2001 and raised its 1st funding round 2 years after it was founded.
CVRx is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
CVRx is a funded company, having raised a total of $368.5M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CVRx is 206.
Annual revenue of CVRx is $51.29M as on Dec 31, 2024.
CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the bodys cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.
CVRx's top competitors include Sequana Medical, Adona Medical and Element Science.
CVRx offers Barostim.
Yes, CVRx is publicly traded on NASDAQ under the ticker symbol CVRX.
CVRx has 21 investors. Key investors include SVB, DaVita, Oxford Finance, Frazier Healthcare Partners, and Piper Jaffray.
The ticker symbol of CVRx is CVRX on NASDAQ.